NASDAQ:CYTT Cyteir Therapeutics (CYTT) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free CYTT Stock Alerts $3.01 -0.01 (-0.33%) (As of 03/18/2024) Add Compare Share Share Today's Range$2.92▼$3.1950-Day Range$3.01▼$3.0152-Week Range$1.65▼$3.19Volume551,300 shsAverage VolumeN/AMarket Capitalization$108.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsSEC FilingsTrendsStock AnalysisChartEarningsFinancialsSEC FilingsTrends Get Cyteir Therapeutics alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Cyteir TherapeuticsCyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.Read More CYTT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTT Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive CYTT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyteir Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYTT CUSIPN/A CIK1662244 Webcyteir.com Phone857-285-4140FaxN/AEmployees46Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.88% Return on Assets-23.83% Debt Debt-to-Equity RatioN/A Current Ratio21.89 Quick Ratio21.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book0.73Miscellaneous Outstanding Shares36,000,000Free Float30,814,000Market Cap$108.36 million OptionableN/A Beta0.09 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Joseph S. Zakrzewski (Age 62)Independent Investor & Independent Chairman of the Board Comp: $81.5kDr. Markus F. Renschler M.D. (Age 63)President, CEO & Director Comp: $718.62kDr. Kevin Mills Ph.D.Co-FounderMr. David G. Gaiero (Age 46)CFO & Treasurer Key CompetitorsTheravance BiopharmaNASDAQ:TBPHPrecigenNASDAQ:PGENContineum TherapeuticsNASDAQ:CTNMKorro BioNASDAQ:KRROErascaNASDAQ:ERASView All Competitors CYTT Stock Analysis - Frequently Asked Questions How have CYTT shares performed in 2024? Cyteir Therapeutics' stock was trading at $3.01 at the beginning of the year. Since then, CYTT stock has increased by 0.0% and is now trading at $3.01. View the best growth stocks for 2024 here. How do I buy shares of Cyteir Therapeutics? Shares of CYTT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYTT) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHistoric NVIDIA partnership could send this tiny AI stock soaring...After striking partnerships with trillion-dollar chipmaker NVIDIA... ARM surged over 60% in a week... Who's...Behind the Markets | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyteir Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyteir Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.